BioCentury
ARTICLE | Finance

Crossovers invest ahead of pre-IPO round, as bispecifics play EpimAb readies to deploy $120M series C

Mirae, Cormorant, Octagon among investors in Shanghai company’s latest venture round

March 23, 2021 1:16 AM UTC

After raising a $120 million series C round co-led by China Merchants Bank International and Mirae Asset Financial Group, EpimAb now turns to executing on its trio of clinical cancer compounds ahead of a pre-IPO financing planned for 2H21 or 1H22.

The financing is the first for the company under CFO David Gu, a McKinsey & Co. and Jefferies alum who joined Shanghai-based EpimAb Biotherapeutics Inc. last March from New York investment firm Millennium Management. ...